EMEugenia Martinez-Hernandez

Eugenia Martinez-Hernandez

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Eugenia Martinez-Hernandez has a total of 548 co-authors. Here are the top co-authors by number of shared publications:

  • Josep Dalmau

    Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain

    38 shared publications
  • Francesc Graus

    Neuroimmunology Program, Fundació de Recerca Clínic Barcelona-Institut d'Investigacions Biomèdiques August Pi i Sunyer (FRCB-IDIBAPS), University of Barcelona, Spain

    30 shared publications
  • Thaís Armangue

    Neuroimmunology Program, Fundació de Recerca Clínic Barcelona-Institut d'Investigacions Biomèdiques August Pi i Sunyer (FRCB-IDIBAPS), University of Barcelona, Spain

    21 shared publications
  • Albert Saiz

    Neuroimmunology Program, Fundació de Recerca Clínic Barcelona-Institut d'Investigacions Biomèdiques August Pi i Sunyer (FRCB-IDIBAPS), University of Barcelona, Spain

    14 shared publications
  • Albert Saiz

    Neuroimmunology and Multiple Sclerosis Unit and Laboratory of Advanced Imaging in Neuroimmunological Diseases (ImaginEM), Hospital Clinic Barcelona, IDIBAPS, Universitat de Barcelona, Barcelona, Spain

    13 shared publications
  • Raquel Ruiz-García

    Department of Immunology, Biomedical Diagnostic Center, Hospital Clínic de Barcelona, Spain; and

    12 shared publications

Latest Publications

  • Open Access

    MOGAD-Like Encephalitic Syndromes Without MOG Antibodies in Children

    by Gemma Olivé-Cirera, Elianet Gisell Fonseca, Mar Guasp, Ludovica Falcioni, Anna Fetta, Raquel Ruiz García, Elisabet Poyatos, Ana Beatriz Serafim, Maria Gual, Gianni Ippoliti, et al.

    Background and ObjectivesAlthough acute disseminated encephalomyelity (ADEM) can be myelin oligodendrocyte glycoprotein-IgG (MOG-IgG) positive or negative, it is unclear whether other MOG-antibody–...

  • Open Access

    Rituximab and IVIG added to plasma exchange improves the outcome of severe CNS demyelinating attacks: a retrospective study

    by Juan Luis Chico-Garcia, Moisés Morales de la Prida, Almudena Boix Lago, José Manuel García-Domínguez, María Sepúlveda, Eugenia Martínez-Hernández, Mar Guasp, Elianet Fonseca, Alberto Calvi, María Teresa Alba-Isasi, et al.

    Background: Plasma exchange (PE) is a therapeutic option for CNS demyelinating attacks unresponsive to corticosteroids, but the potential benefit of adding rituximab and IV immunoglobulins to PE (RTX-IVIG-PE), which has shown its efficacy and safety in other immune-mediated conditions, has not been investigated. Objective: We aimed to determine the overall effectiveness of PE in severe demyelinating attacks, identify predictors of response, and compare outcomes between standard PE and RTX-IVIG-PE protocols. Design: Retrospective analysis of patients with CNS demyelinating attacks treated with PE between 2012 and 2023 across five Spanish hospitals. Methods: Clinical response was measured as an improvement or a complete recovery at discharge and 6 months. Uni- and multivariable logistic regression models were developed to identify predictors of PE response. A logistic regression analysis, after inverse probability of treatment weighting (IPTW), was performed to compare the outcome of attacks treated with standard PE and RTX-IVIG-PE. Results: A total of 162 attacks in 150 patients (81 multiple sclerosis; 37 others acquired demyelinating syndromes; 27 neuromyelitis optica spectrum disorder; 5 myelin oligodendrocyte glycoprotein antibody-associated disease; 73% female; median age 43 years (interquartile range 33–52.75)) were analyzed. At discharge, 60% of all attacks showed clinical improvement, and 15% achieved complete recovery. At 6 months, these rates increased to 77% and 31%, respectively. Younger age, lower preattack Expanded Disability Status Scale, and treatment with RTX-IVIG-PE were independent predictors of complete recovery at 6 months. IPTW analysis showed that attacks treated with RTX-IVIG-PE (33) were associated with improvement (adjusted odds ratio (aOR) 5.4, p < 0.001) and complete recovery (aOR 4.55, p < 0.001) at 6 months compared to those treated with standard PE (129), without significant differences in the adverse event profile between the two protocols. Conclusion: PE improves the outcome of steroid-refractory CNS demyelinating attacks, and the addition of rituximab and IVIG to PE may increase the likelihood of long-term recovery.


  • Open Access

    HLA and T-Cell Receptor Investigations in Idiopathic and Paraneoplastic Opsoclonus-Myoclonus in Children

    by Gemma Olivé-Cirera, Guillermo Muñoz-Sánchez, Eduard Palou, Raquel Ruiz García, Elianet Gisell Fonseca, Juan Francisco Luchoro, Sergio Aguilera-Albesa, Estibaliz Maudes, Eugenia Martinez-Hernandez, Lidia Sabater, et al.

    Opsoclonus-myoclonus-ataxia syndrome (OMAS) is a rare pediatric autoimmune neurologic disorder, with 40%-50% of cases occurring as a paraneoplastic syndrome in the setting of neuroblastoma or other neuroblastic tumors. The strong clinical similarities between idiopathic and paraneoplastic OMAS have led to the hypothesis that neuroblastoma may initially be present in idiopathic cases but spontaneously regress before OMAS onset. Both B- and T-cell mechanisms appear to contribute to OMAS autoimmunity, although their precise roles remain unknown. The aim of this study was to investigate similarities and differences between idiopathic and paraneoplastic OMAS by analyzing HLA profiles and T-cell receptor (TCR) repertoires in a Spanish pediatric cohort. Children with OMAS were enrolled in a nationwide prospective study (2013-2024). Neural autoantibody testing was performed in all patients. HLA genotyping was performed using next-generation sequencing (GenDx/Illumina) and compared with a reference Spanish population (n = 4,335). The Benjamini-Hochberg false discovery rate method was used to control for multiple comparisons across HLA antigens. TCR repertoires were analyzed in peripheral blood samples of 12 patients using the Adaptive Biotechnologies immunoSEQ assay. The bioinformatics tool Grouping of Lymphocyte Interactions by Paratope Hotspots (GLIPH2) was used to identify shared motifs within CDR3β-TCR sequences. Among 25 children with OMAS (median age 22 months [interquartile range (IQR): 15-38]), 12 (48%) had neuroblastoma and 3 (12%) had neuronal antibodies (one with anti-Hu, one with anti-myelin oligodendrocyte glycoprotein, one against unknown neuronal surface antigens). Some HLA class II antigens (DRB1*08, DRB1*10, and DQB1*04) were consistently overrepresented in patients with OMAS compared with Spanish controls (all p-adjusted p-adjusted <0.05), suggesting subgroup-specific genetic risks. TCR analysis revealed that patients with paraneoplastic OMAS showed greater TCR repertoire similarity, whereas shared sequences were rare in idiopathic OMAS. Despite similar clinical presentations, idiopathic and paraneoplastic OMASs appear to have distinct immunopathogenic mechanisms. In paraneoplastic OMAS, enrichment of specific HLA antigens and convergent TCR profiles supports antigen-driven T cell-mediated autoimmunity.

  • Open Access

    Cytokine and Chemokine Profiles in Anti-LGI1 Encephalitis

    by Guillermo Muñoz-Sánchez, Mar Guasp, Amaia Muñoz-Lopetegi, Juan Francisco Luchoro, Eugenia Martínez-Hernández, Laura Naranjo, Maria Elena Erro, Lorena Martín-Aguilar, Takahiro Iizuka, Mateus Mistieri Simabukuro, et al.

    Anti-leucine-rich glioma-inactivated 1 (anti-LGI1) encephalitis is the most common antibody-mediated encephalitis in adults older than 50 years. In addition to antibody effects, cytokines and chemokines drive neuroinflammation in other autoimmune encephalitides. However, their role in anti-LGI1 encephalitis is underexplored. We evaluated cytokine profiles in serum and CSF, correlating them with acute severity and long-term outcome. Cytokine/chemokine levels from 57 untreated patients with anti-LGI1 encephalitis were measured in serum and CSF (34 paired samples) with a bead-based multiplex assay and compared with those of patients with noninflammatory neurologic disorders (serum = 24; CSF = 21). Clinical information including degree of severity (modified Rankin Scale, mRS) and 12-month functional outcomes (resume previous activities and work) was assessed. Patients with anti-LGI1 encephalitis exhibited an increased proinflammatory profile in CSF and serum, with elevated levels of IL-1β, IL-1RA, IL-6, IL-8, IL-10, IL-18, IL-35, IP-10, granzyme B, CX3CL1, MIG, TNFα, and SDF1. A higher CSF/serum IL-6 ratio correlated with disease severity at onset (mRS score >2: 1.67 [0.50-7.20] vs 0.39 [0.07-1.22], p = 0.0069). Elevated acute-phase serum IL-35 predicted poorer 12-month outcomes (81.34 vs 9.19 pg/mL in partial vs complete recovery, p = 0.0003). Increased B cell-related markers (IL-21, BAFF, APRIL, CXCL13) in CSF (all p < 0.05) were also observed. In this study, we show that the acute-phase IL-6 CSF/serum ratio and serum IL-35 levels in immunotherapy-naive patients with anti-LGI1 encephalitis are associated with disease severity and poor outcomes, respectively, highlighting their potential as biomarkers for risk stratification and therapeutic targeting.


  • Open Access

    Diffusivity anisotropy signature of slowly expanding lesions predicts progression independent of relapse activity in multiple sclerosis

    by Alberto Calvi, Francesc Vivó Pascual, Elisabeth Solana, Elisabet Lopez-Soley, Baris Kanber, Salut Alba-Arbalat, Maria Sepulveda, Eugenia Martínez-Hernández, José Maria Cabrera-Maqueda, Elianet Fonseca, et al.

    Background Slowly expanding lesions (SELs) in multiple sclerosis (MS) are markers of chronic active lesions and seem to trigger disability. This study aimed to analyse spatial features of SELs through diffusion MRI and their clinical impact on progression independent of relapse activity (PIRA). Methods An observational study of MS subjects prospectively followed since 2011; inclusion required at least three longitudinal T1/T2-weighted and diffusion-weighted MRIs. Subjects followed clinical assessments, using Multiple Sclerosis Functional Composite (MSFC) and Expanded Disability Status Scale. At MRI, lesions were categorised using non-linear deformation as definite or possible SELs, and non-SELs. Fractional anisotropy (FA) was extracted from each lesion core and perilesional area. Differences in FA values across core and perilesional areas by SEL category were assessed using the Mann-Whitney test. Associations with PIRA and clinical outcomes were evaluated using mixed-effects, logistic and Cox regression models. Results 130 subjects underwent MRI (median 25 months) and clinical assessments (median follow-up 9.2 years), of which 29 (22%) developed PIRA. Of 4811 lesions, 8% were definite SELs. Definite SELs exhibited FA decline over time in core and perilesional areas compared with other lesions. Longitudinal core FA reductions within definite SELs were associated with worse MSFC z-score evolution (β=0.03, 95% CI 0.01 to 0.05, p=0.003), higher odds for PIRA (OR=0.01, 95% CI 0.01 to 0.12, p=0.001) and predicted faster time to reach first PIRA event (HR=0.03, 95% CI 0 to 0.49, p=0.015). Conclusions Definite SELs show distinct greater microstructural damage and are associated with PIRA, making their FA signature a potential predictor of MS progression.


  • Open Access

    Clinical Characterization and Long-Term Outcome in Children and Adults With Anti-AMPA Receptor Encephalitis

    by Chiara Milano, Ezgi Saylam, Claudia Papi, Laura Marmolejo, Alexandra Sankovic, Raphael Reinecke, Jeroen Kerstens, Chiara Pizzanelli, Mateus Mistieri Simabukuro, Marie Benaiteau, et al.

    Anti-alpha-amino-3-hydroxy-5-methyl-4-isoxazole-propionic acid receptor (anti-AMPAR) encephalitis manifests as limbic encephalitis in adults and is often associated with cancer. Although some reports suggest that it may occur in children, the clinical features in this population, as well as the prognostic factors and long-term outcomes in children and adults, are unknown. We performed a retrospective, international collaborative study of patients with anti-AMPAR encephalitis. Clinical information was reviewed, together with data from published pediatric patients. Clinical features of children and adults were compared with nonparametric tests. Survival rates (Kaplan-Meier curves) were compared using log-rank tests. Prognostic factors of poor outcome (modified Rankin Scale score >2) were identified using logistic regression models. A total of 115 patients were included, of whom 84 (71 adults, 13 children) had only AMPAR antibodies and 31 (27 adults, 4 children) had additional concurrent neural antibodies. Among patients with AMPAR antibodies alone, tumors were identified in 37 adults (56%) and none of the children (p < 0.0001). Children were more likely than adults to have behavioral/psychiatric symptoms (5/13, 39%, vs 8/71, 11%, p = 0.026) at onset, cerebellar dysfunction (6/13, 46%, vs 7/68, 10% p = 0.005) or movement disorders (5/13, 39%, vs 8/67, 12%, p = 0.032) during the disease course, and extratemporal brain MRI lesions (4/9, 44%, vs 5/44, 11%, p = 0.035). Among 34 patients with prolonged follow-up (>24 months), long-term neurocognitive sequelae were reported in 23 (68%), all adults. Failure to respond to first-line immunotherapy at multivariable analysis predicted a poor outcome (OR 8.0, 95% CI 1.1-59.2, p = 0.043). Among the 31 patients with concurrent neural autoantibodies, 22 (79%) had a tumor; those with high-risk antibodies had lower survival rates (p = 0.008). Children and adults with anti-AMPAR encephalitis show distinct clinical-radiologic features. At long-term follow-up, 68% of patients, all adults, have neurologic sequelae, with failure to respond to first-line immunotherapy being associated with worse outcomes.


  • Open Access

    Autologous Hematopoietic Stem Cell Transplantation for Paraneoplastic Cerebellar Degeneration

    by Victor Guerra, Jose Maria Cabrera-Maqueda, Raquel Ruiz-Garcia, Juan Francisco Luchoro, Elianet Fonseca, Mar Guasp, Yolanda Blanco, Maria Suarez-Lledo, Francesc Fernandez-Aviles, Carmen Martinez, et al.

    The aim of this study was to describe 2 patients with paraneoplastic cerebellar degeneration (PCD) treated with autologous hematopoietic stem cell transplantation (AHSCT). Off-label AHSCT was performed at Hospital Clinic Barcelona, including stem cell mobilization (cyclophosphamide, filgrastim), plasma exchange, and a nonmyeloablative regimen (cyclophosphamide, antithymocyte globulin, rituximab [RTX]). A 38-year-old woman developed anti-Yo-associated PCD 17 months after treatment of a gynecologic cancer (without evidence of tumor recurrence). Despite treatment with steroids and RTX, she became unable to walk. AHSCT resulted in progressive improvement, no longer needing assistance to walk 9 months after AHSCT. Tumor recurrence, without neurologic worsening, was identified 16 months after AHSCT, and chemotherapy was restarted. At the last follow-up (46 months), she continues on chemotherapy without neurologic deterioration. A 48-year-old man developed PCD associated with Tr/delta/notch-like epidermal growth factor-related receptor antibodies. Axillary lymph node biopsy demonstrated Hodgkin lymphoma. Chemoradiation resulted in complete tumor response, but cerebellar ataxia worsened despite treatment with steroids and IV immunoglobulins. Ten months after cerebellar symptom onset, he underwent AHSCT resulting in neurologic improvement. At the last follow-up, 39 months after AHSCT, he remains independent in activities of daily living. In our experience, AHSCT is worth to be considered in patients with progressive PCD refractory to conventional oncological and immunotherapy treatments. This is a single observational study without controls and provides Class IV evidence.


  • Open Access

    Clinical Features of Children With MOG-IgG Who Fulfill Criteria of Multiple Sclerosis and Overlapping Disorders

    by Elianet Gisell Fonseca, Gemma Olivé-Cirera, Li-Wen Chen, Fernando Paredes-Carmona, Noemí Nuñez Enamorado, Sabas Boyero Duran, Maria del Mar Mendibe, Núria Visa-Reñé, María Vázquez-López, Ana Felipe-Rucián, et al.

    The aim of this study was to report the clinical features, disease-modifying treatment (DMT) response, and outcomes of children with MOG-IgG who fulfill the 2017 McDonald criteria for multiple sclerosis (MS). This prospective observational study included children (<18 years) with a suspected acquired demyelinating syndrome (ADS) whose serum or CSF was positive for MOG-IgG, who met the indicated MS criteria, and who had ≥1 year of clinical follow-up. MOG-IgG was tested using live cell-based assays. Of 554 children with confirmed ADS (196 with MOG-IgG), 8 (median age 11 years, interquartile range 9–14) harbored MOG-IgG and fulfilled MS criteria: 2 had typical MS and 6 had overlapping MOGAD-MS features at onset, but 5 of the latter group developed an MS-like course during follow-up. Five of 7 patients with assessable samples were Epstein-Barr virus seropositive at disease onset, and all 8 had persistent silent radiologic activity with lesional location and morphology suggestive of MS, leading to initiation of DMT. All initial treatments were well tolerated, but eventually, 7 of 8 children (88%) required high-efficacy DMT. In this pediatric cohort, 4% of patients with MOG-IgG met criteria for MS. The clinical-radiologic spectrum ranged from typical MS to overlapping MOGAD-MS, and patients usually required high-efficacy DMT.


  • Open Access

    Assessing Commercial Tissue-Based Assays for Autoimmune Neurologic Disorders (II)

    by Claudia Papi, Chiara Milano, Lionel Arlettaz, Pietro Businaro, Laura Marmolejo, Laura Naranjo, Jesús Planagumà, Eugenia Martinez-Hernandez, Thaís Armangué, Mar Guasp, et al.

    Detecting neural surface antibodies (NSAbs) is essential for diagnosing autoimmune encephalitis. The recommended diagnostic strategy involves initial screening with tissue-based assays (TBAs), followed by confirmation with cell-based assays (CBAs). While specialized centers use in-house TBAs, many clinical laboratories depend on commercial TBAs, whose accuracy is yet to be fully assessed. We selected 92 CSF and 99 serum samples from patients with autoimmune encephalitis and NSAbs confirmed by in-house TBAs and CBAs (20 samples each for AMPAR, GABAAR, GABABR, IgLON5, LGI1, NMDAR, and CASPR2; 19 for mGluR5; 17 for DPPX; and 15 for mGluR1 antibodies), along with 50 CSF and 50 serum samples from negative controls. We assessed the performance of a commercial indirect immunofluorescence (IIF)-TBA (EUROIMMUN). Slides were evaluated as "positive" or "negative" by 2 experienced investigators and 2 less experienced raters. Discordant results were re-evaluated through interrater discussion and assessed using Cohen's kappa. The experienced raters agreed on 94% (133/142) of CSF and 88% (131/149) of serum classifications (Cohen's kappa = 0.87 and 0.75, respectively, p < 0.001). Among CSF samples, 75% (106/142) were correctly identified while 19% (27/142) were misclassified (13 false positives, 14 false negatives). Among serum samples, 66% (98/149) were correctly identified while 22% (33/149) were misclassified (11 false positives, 22 false negatives). The poorest performance was seen in detecting NMDAR, GABAAR, and mGluR5 Abs, which were not identified in 5 of 10, 6 of 10, and 5 of 9 serum samples and in 4 of 10, 5 of 10, and 5 of 10 CSF samples, respectively. The overall sensitivity of the commercial IIF-TBA was 84% for CSF and 76% for serum while the specificity was 72% for CSF and 73% for serum. Less experienced raters correctly identified 69% (98/142) of CSF samples and 73% (109/149) of serum samples and misclassified 13% (18/142) of CSF samples and 11% (16/149) of serum samples, and 18% (26/142) of CSF samples and 16% (24/149) of serum samples remained discordant. The diagnostic performance of EUROIMMUN IIF-TBA in detecting NSAbs in autoimmune encephalitis is suboptimal. NMDAR antibodies, among the most common NSAbs, can be missed in 50% of cases. This commercial TBA should not be used alone as a screening method nor as a confirmatory technique for NSAbs.


  • Open Access

    Assessing Commercial Tissue-Based Assays for Autoimmune Neurologic Disorders (I)

    by Chiara Milano, Pietro Businaro, Claudia Papi, Lionel Arlettaz, Laura Marmolejo, Laura Naranjo, Matteo Gastaldi, Raffaele Iorio, Albert Saiz, Jesús Planagumà, et al.

    Current strategies to detect autoantibodies against intracellular neural antigens (IC-Abs) include tissue-based assays (TBAs) alongside line blots or cell-based assays (CBAs). Many clinical laboratories use commercially available TBAs as a screening test, but their diagnostic yield has not been assessed. We determined the performance of 2 commercial TBAs in detecting IC-Abs. We analyzed samples from 100 patients with autoimmune or paraneoplastic neurologic syndromes harboring IC-Abs (confirmed by in-house TBAs and line blots or CBAs) and 50 negative controls. IC-Abs samples included serum (10 each for Hu, Yo, Ri, SOX1, CV2, Ma2, Tr, amphiphysin, and GAD65 antibodies) or CSF (10 with GFAP antibodies) samples. Two commercial indirect immunofluorescence (IIF) TBAs (INOVA and EUROIMMUN) were assessed by 2 experienced investigators and 3 less experienced raters, all blinded to antibody status. Discordant results were re-evaluated through interrater discussion and assessed using Cohen's kappa. The 2 experienced raters showed substantial agreement (85% for INOVA, 83% for EUROIMMUN) on negative/positive results, which increased to >95% after interrater discussion (Cohen's kappa 0.95 and 0.93, respectively). With IIF-INOVA, they correctly identified 118 of 150 samples (79%) and misclassified 28 of 150 (19%, 2 false positives and 26 false negatives) while results remained discordant in the remaining 4 of 150 samples (2%). With IIF-EUROIMMUN, they correctly identified 105 of 150 samples (70%) and misclassified 40 of 150 (27%, 6 false positives, 34 false negatives), with discordance in 5 of 150 samples (3%). Overall, the sensitivity was 73% for IIF-INOVA and 66% for IIF-EUROIMMUN. The specificity was 96% for IIF-INOVA and 88% for IIF-EUROIMMUN. Both TBAs showed low sensitivity in detecting CV2, SOX1, and amphiphysin antibodies while Ma2 antibodies were missed mainly by IIF-EUROIMMUN and Hu/Ri antibodies by IIF-INOVA. Antibody-specific immunostaining patterns were correctly identified in 62 of 100 positive samples with IIF-INOVA and 55 of 100 with IIF-EUROIMMUN (p = 0.34). Less experienced raters showed higher rates of false-positive results (up to 22% with IIF-EUROIMMUN). The performance of commercial IIF-TBAs for IC-Abs detection is suboptimal, exhibiting high false-negative rates of 25%-35%. Therefore, commercial TBAs should not be used alone for IC-Abs screening, but alongside more sensitive techniques, such as line blots. Discordant results between 2 techniques should prompt retesting in reference centers with in-house TBAs, particularly when the suspicion of an autoimmune or paraneoplastic syndrome is high.